Palisade Bio (PALI) Corporate presentation summary

Mission and strategic focus

• Advancing next-generation oral prodrugs for inflammatory and fibrotic diseases, with a lead focus on IBD, including ulcerative colitis (UC) and Crohn's disease (CD).

• PALI-2108 is the first oral PDE4 inhibitor prodrug specifically engineered for IBD, targeting a multi-billion-dollar market.

• Differentiated by local gut activation, aiming for improved efficacy and tolerability over systemic PDE4 inhibitors.

• Supported by strong financial backing from institutional healthcare investors.

• Biomarker strategy in development to optimize patient selection and response.

Market opportunity and patient preference

• IBD affects approximately 6 million patients globally, with the market expected to reach $41 billion by 2032.

• Oral therapies are highly preferred by IBD patients, with 91% rating oral tablets as highly acceptable compared to 34% for injections.

• Once-daily oral dosing is favored for convenience and adherence.

PALI-2108 mechanism and differentiation

• Gut-activated prodrug design enables targeted PDE4 inhibition in the ileum and colon, minimizing systemic exposure and side effects.

• Dual-action mechanism delivers both anti-inflammatory and anti-fibrotic effects.

• Demonstrates 10-20x higher potency and 6-7x greater drug exposure in target tissues versus plasma.

• Improved tolerability profile compared to non-localized PDE4 inhibitors.